^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    INSM1 (INSM Transcriptional Repressor 1)

    i
    Other names: INSM1, INSM Transcriptional Repressor 1, IA1, Insulinoma-Associated Protein 1, Zinc Finger Protein IA-1, Insulinoma-Associated 1, IA-1, Insulinoma Associated 1
    Associations

    News

    Trials
    15d
    Molecular subtyping of small-cell lung cancer in clinical practice: Primary tumor-lymph node concordance, intratumoral heterogeneity, and genomic context in a Chinese cohort. (PubMed, Lung Cancer)
    The observed discordance during regional nodal dissemination suggests that single site-dependent immunohistochemistry-based subtyping may be insufficient. Future frameworks incorporating multi-region analysis and liquid biopsy are essential to capture the dynamic evolution of SCLC and optimize personalized management for localized disease.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • SLFN11 (Schlafen Family Member 11) • CREBBP (CREB binding protein) • YAP1 (Yes associated protein 1) • NFIB (Nuclear Factor I B) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • CASP10 (Caspase 10) • INSM1 (INSM Transcriptional Repressor 1) • NEUROD1 (Neuronal Differentiation 1)
    3ms
    Regulation of INSM1 Gene Expression and Neuroendocrine Differentiation in High-Risk Neuroblastoma. (PubMed, Biology (Basel))
    INSM1 overexpression in SH-SY-5Y cells upregulated neuroendocrine and thyroid hormone-related genes (CHGA, CHGB, DDC, NCAM1, DIO3, TH), while suppressing genes involved in cell cycle (RRM, CDC25A), methionine metabolism (AHCY, MAT2A), transcriptional regulation (MYBL2, EZH2), and oncogenic signaling (ALK, LINC011667). These findings suggest that INSM1 promotes NB aggressiveness by sustaining a neuroendocrine progenitor-like phenotype through metabolic-epigenetic coupling.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NCAM1 (Neural cell adhesion molecule 1) • MYBL2 (MYB Proto-Oncogene Like 2) • CDC25A (Cell Division Cycle 25A) • CHGA (Chromogranin A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • INSM1 (INSM Transcriptional Repressor 1) • MAT2A (Methionine Adenosyltransferase 2A)
    4ms
    Prognostic utility of baseline ASCL1/INSM1 expression and neutrophil-lymphocyte ratio in unresectable SCLC treated with first-line chemoimmunotherapy with or without radiotherapy. (PubMed, Front Med)
    The ASCL1/INSM1-NLR composite biomarker stratifies survival outcomes for unresectable SCLC patients treated with first-line chemoimmunotherapy with or without radiotherapy. Prospective multicenter validation is required.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • INSM1 (INSM Transcriptional Repressor 1) • NEUROD1 (Neuronal Differentiation 1)
    4ms
    Sinonasal Lymphoepithelial Carcinoma With Insulinoma-Associated Protein 1 (INSM1) Expression: A Potential Pitfall. (PubMed, Int J Surg Pathol)
    This case report highlights a potential diagnostic pitfall, as INSM1 expression may be misleading in EBV-associated carcinomas lacking true neuroendocrine differentiation. Integration of morphology, immunoprofile, and EBV status is essential to avoid misclassification.
    Journal
    |
    SYP (Synaptophysin) • INSM1 (INSM Transcriptional Repressor 1)
    4ms
    INSM1 governs a neuronal progenitor state that drives glioblastoma in a human stem cell model. (PubMed, Nat Commun)
    INSM1 is highly expressed in human glioblastoma tumors and, during cortical development, in intermediate progenitor cells, which give rise to neurons. Remarkably, INSM1 knockdown in triple mutant NSCs and primary glioblastoma cells disrupts oncogenic gene expression and function and inhibits the in vivo tumorigenicity of triple mutant NSCs, highlighting the functional importance of an intermediate progenitor cell-like cell state in glioblastoma pathogenesis.
    Journal
    |
    TP53 (Tumor protein P53) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • INSM1 (INSM Transcriptional Repressor 1)
    |
    TP53 mutation • PDGFRA mutation
    6ms
    Immunohistochemical expression of Ki-67, INSM1, and SSTR2A in medullary thyroid carcinoma: correlation with tumour size, vascular invasion, and biochemical outcome. (PubMed, Virchows Arch)
    Among all comparisons, only SSTR2A expression significantly differed between DTs and other tumours. In conclusion, Ki-67 and INSM1 identify patients with more aggressive MTC, while SSTR2A defines a favourable subgroup with complete remission.
    Journal
    |
    SSTR (Somatostatin Receptor) • INSM1 (INSM Transcriptional Repressor 1)
    7ms
    Updating the genomic and clinicopathologic features of thoracic SMARCA4-deficient undifferentiated tumor: a mini-series including a long-term survivor. (PubMed, Front Oncol)
    In this limited series, mutational signature analysis revealed evidence of SBS87 as the predominant single-base substitution COSMIC signature. Our work expands the possible diagnostic antigen expression of thoracic SMARCA4-dUT, contributes to the emerging reports on patients with variant disease presentation, and highlights the need for large-scale genomic studies to determine additional mechanisms of the initiation of carcinogenesis.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • WT1 (WT1 Transcription Factor) • NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin) • INSM1 (INSM Transcriptional Repressor 1)
    |
    TP53 mutation
    9ms
    Simultaneous expression of CD5 and INSM1 may distinguish parotid CASTLE from other primary tumors with a squamous phenotype. (PubMed, Ann Diagn Pathol)
    In summary, simultaneous CD5 and INSM1 expression may serve as a distinct feature for parotid CASTLE, facilitating differential diagnosis in salivary gland pathology. In addition, EBER ISH remains essential to exclude LEC.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • INSM1 (INSM Transcriptional Repressor 1)
    11ms
    Expression of insulinoma-associated protein 1 (INSM1) in gastric neuroendocrine and non-neuroendocrine neoplasms. (PubMed, Discov Oncol)
    INSM1 nuclear positivity in gastric neoplasms should be interpreted with caution. INSM1 should not be used as a stand-alone marker for determining neuroendocrine differentiation in gastric tumors. Histologic evaluation with concurrent use of traditional neuroendocrine markers is warranted to accurately demonstrate neuroendocrine differentiation and minimize false positivity and false negativity.
    Journal
    |
    SYP (Synaptophysin) • INSM1 (INSM Transcriptional Repressor 1)
    1year
    Structural insights into a highly flexible zinc finger module unravel INSM1 function in transcription regulation. (PubMed, Nat Commun)
    Instead, INSM1 collaborates with CTCF to target genome loci having the GGGG-contained element and regulate the expression of adjacent genes. This study defines a functional mode of INSM1 by cooperating with diverse DNA-binding proteins for targeting specific genome loci in transcription regulation, and provides structural information for designing INSM1-related therapeutic drugs and diagnostic probes.
    Journal
    |
    INSM1 (INSM Transcriptional Repressor 1) • TEAD1 (TEA Domain Transcription Factor 1)
    1year
    The Expression of Neuroendocrine Markers in a Small Subset of Ameloblastoma with Implications of Clusterin. (PubMed, Cells)
    SYP-positive and CgA-negative phenotypes may characterize neuroendocrine differentiation in ameloblastoma. Although the underlying molecular mechanism remains unclear, CLU expression may be associated with neuroendocrine differentiation.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • CLU (Clusterin) • SYP (Synaptophysin) • INSM1 (INSM Transcriptional Repressor 1)